Aktiv-dry, LLC

Boulder, CO 80301

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $2.64MM
First Award Date 01/01/04
Most Recent Award Date 06/01/13

Key Personnel

Last Name Name Awards Contact
Cape Stephen P Cape 3
Searles James Arthur Searles 2
Quinn Brian Quinn 4 Message
Pathak Pankaj Pathak 1
Sievers Robert Sievers 1 Message

10 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 06/01/13 - 05/31/14

DESCRIPTION (provided by applicant): The overarching goal of this project is to move a new, dry powder formulation of Hepatitis-B vaccine on its path to commercialization. In the Phase I SBIR we tested in vitro three Hep-B dry powder formulations of commercially available Shanvac-B and demonstrated powder stability and immunogenicity at temperat...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 06/30/12 - 05/31/13

DESCRIPTION (provided by applicant): The overarching goal of this project is to move a new, dry powder formulation of Hepatitis-B vaccine on its path to commercialization. In the Phase I SBIR we tested in vitro three Hep-B dry powder formulations of commercially available Shanvac-B and demonstrated powder stability and immunogenicity at temperat...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-OD-09-009
Budget: 04/05/10 - 03/31/12

DESCRIPTION (provided by applicant): Assuring the success of mass campaigns against bioterrorist or naturally occurring pathogens requires that vaccines, therapeutics, and other products are stored and ready for immediate use at the time the threat to public health is perceived. Storage is a major contributor to the cost of administration under ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-006
Budget: 06/01/09 - 05/31/11

DESCRIPTION (provided by applicant): Aktiv-Dry LLC, in collaboration with Nabi Biopharmaceuticals, proposes to develop and evaluate in animal models the needle-free respiratory delivery of fine dry powder nicotine vaccine. While syringe and needle have been a common vaccine administration mechanism, international authorities recognize a growing ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 09/01/08 - 05/31/09

DESCRIPTION (provided by applicant): Aktiv-Dry LLC, in collaboration with Nabi Biopharmaceuticals, proposes to develop and evaluate in animal models the needle-free respiratory delivery of fine dry powder nicotine vaccine. While syringe and needle have been a common vaccine administration mechanism, international authorities recognize a growing ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 06/01/08 - 05/31/10

DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project aims to develop a novel dry powder inhalation system, Aktiv-NebTM, for delivering antiviral drug (siRNAs) powders, to the respiratory systems of infants and young children as an intervention strategy for respiratory infection RSV. RSV-specific siRNAs dev...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 09/01/06 - 05/31/08

DESCRIPTION (provided by applicant): Aktiv-Dry LLC, in collaboration with Nabi Biopharmaceuticals, proposes to develop and evaluate in animal models the needle-free respiratory delivery of fine dry powder nicotine vaccine. While syringe and needle have been a common vaccine administration mechanism, international authorities recognize a growing ...

Phase 2 SBIR

Agency: Department of Agriculture
Topic: 2006
Budget: 01/01/06 - 12/31/06

Commercially available products rich in phytosterol may now be used to cut serum low-density lipoprotein by as much as 14 percent. Unfortunately, phytosterols are poorly soluble and therefore present unique problems concerning their ability to suppress cholesterol absorption in the gut. This impediment often leads to sub-optimal dosing and poor ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/02/04 - 06/30/06

DESCRIPTION (provided by applicant): This Phase I SBIR proposal is the first step in the development of inhalable IgG microparticles for immunoprophylaxis against Influenza A, a category C Priority Pathogen. In Phase I, Aktiv-Dry will simultaneously stabilize, dry, and micronize IgG antibody solutions by a newly patented process, Carbon Dioxide...

Phase 1 SBIR

Agency: Department of Agriculture
Topic: 2004
Budget: 01/01/04 - 12/31/04

Phytosterols and lycopene are neutraceuticals that are known antioxidants and cancer inhibitors. Unfortunately, they do not dissolve readily in body fluids and therefore present unique problems concerning their uptake by the blood stream. This project explores the ability to enhance the rate of solubility of lycopene and phytosterols by formulat...

Load More